Some Valeant Pharma (NYSE: VRX) creditors said to resist proposal to relax loan pact, according to Bloomberg. Some lenders are said looking for higher fees and rates, sources noted.
UPDATE - Valeant needs to get approval of the measures from over half of investors holding some $11 billion in secured loans. The company has around $32 billion in total debt.
Creditors also want to impose some restrictions on the terms that the company is offering in its proposal, sources noted.
Valeant didn't immediately respond to a request for commentary
Valeant Pharma (VRX) creditors said to resist proposal to relax loan pact - Bloomberg
Deutsche analyst Nandan Amladi also cut his PT to $35 (from $50), saying that the slowdown in Verint's emerging market business and slower-than-expected enterprise growth will weigh on results going forward.
Credit Suisse analyst Michael Nemeroff, meanwhile, slashes his PT to $29 (from $45), arguing that Verint lacks near-term catalysts to drive the stock higher.
Un-real & u idiots are buying into this BS? So now we have to wait for bankruptcy in May in stead of April. Oh well I can wait another month for this pos to go to ZERO!
That's a 14% increase! 34.5% of the float. All time high short interest, while the stock price is at a 2 year low. Not good! Look for AMAG to slide back down to $15 or less. If long, cut your loses & move on. Amag is a dog!
Poor tucker his #$%$ got pucker when he bought this MF at $40 suckers... LOl... Keep buying those dips you fool!
Earning estimates must be falling like a cheap $10 #$%$. Watch for a major reduction in earnings & revenue. I would say in the neighbor of 30% to %40.AMAG will definitely tank to $10
3/28/2016 Robert W. Baird Lower Price Target Outperform $26.00 - $25.00 View Rating Details Tweet This Rating Share This Rating on StockTwits
3/28/2016 Leerink Swann Lower Price Target Outperform $25.00 - $23.00 View Rating Details Tweet This Rating Share This Rating on StockTwits
3/28/2016 Ladenburg Thalmann Downgrade Buy - Neutral View Rating Details Tweet This Rating Share This Rating on StockTwits
3/28/2016 Jefferies Group Upgrade Underperform - Hold $16.00 - $19.00
The chief executive of Valeant Pharmaceuticals International Inc (VRX.TO), which is under scrutiny for hiking the price of older drugs, has been summoned to testify at a U.S. congressional hearing on April 27. The Senate Special Committee on Aging hearing comes as the Canadian-based company is coping with a variety of federal investigations into its accounting practices.
AAAAh the poster child loser who loves to delete his postings. FYI loser I bought another 4000 shares at $21 bringing my average under $25.50. Sold all 9000 shares at $27.30 & $27.33. Un-like you loser who is still holding from the mid forties.. Can we say loser? Loser.....
Sure hope you took my advice & sold this pos for a small profit. Other wise welcome to the bagholder club! Enjoy! See you at $15......
How's that long position working out for you slim? Lol... Like I said, Amag is heading to the mid teens. After all earnings are around $.80 to $1.00 for 2016. $1 Billion in debt, & no new drugs in the pipeline. At best fair value is around $10 to $15.
Earning estimates are base on Gaap estimate's. Non-gaap earnings is around .80 to $1.00. Also Amag has no pipeline for new drugs. Amag looks cheap , but it's not. Sell now before they gap it down in the low teens.
Barclays Downgrade Overweight - Equal Weight $135.00 - $34.00 Dang $100 drop in pt. Hell why not just say ZERO!
Mizuho Securities downgraded Valeant Pharmaceuticals from Neutral to Underperform with a price target of $18.00 (from $70.00).
"After careful consideration of comments from the earnings call, we view 3-year growth forecasts as unreliable and see the business as contracting," analyst Irina Koffler commented. "We also expect erosion of the company's topline to exceed the exclusivity risk guided by Valeant due to heavier rebating and divestitures required for debt repayment."
Koffler said they don't trust Valeant's 2016 or 3-year growth forecasts and our 2016 estimates are lower (i.e., they model $10.4B in revenue and $8.04 EPS relative to guidance of $11.0-11.2B and $8.50-9.50).
They also worry about liquidity and an ongoing insider trading class action suit that they believe could burden the liability side of the balance sheet.
The Underperform rating is predicated on an equally weighted combination of DCF analysis ($15) and a more conservative SOTP that employs lower sales multiples applied to updated 2015 numbers ($21) for a blended $18 PT.